Association of two variants in IL-1β and IL-1 receptor antagonist genes with multiple sclerosis

Journal of Neuroimmunology

Volumn 106, Issue 1-2, 2000, Pages 220-227

  Kantarci, Orhun H ^a   Atkinson, Elizabeth J ^a   Hebrink, David D ^a   McMurray, Cynthia T ^b   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Genetics; IL 1 receptor antagonist; Interleukin 1; Multiple sclerosis; Prognosis; Susceptibility

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; TANDEM REPEAT; UNITED STATES;

ADULT; ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; VARIATION (GENETICS);

EID: 0034237667     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00202-2     Document Type: Article

References (34)

1. Altintas, A., Kantarci, O., Hekim, N., Öztuzcu, S., Saip, S., Siva, A., 1997. Serum and CSF cytokine levels in different forms of Multiple Sclerosis. (Abstract) Multiple Sclerosis, Clinical and laboratory research 3 (5), 313: P119.
2. Arend W.P. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest. 88:(5):1991;1445-1451.
3. Bioque G., Crusius J.B., Koutroubakis I., Bouma G., Kostense P.J., Meuwissen S.G., Pena A.S. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1ra) genes in inflammatory bowel disease. Clin. Exp. Immunol. 102:1995;379-383.
4. Bioque G., Bouma G., Crusius J.B., Koutroubakis I., Kostense P.J., Meuwissen S.G., Pena A.S. Evidence for genetic heterogeneity in IBD.1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8:1996;105-110.
5. Brinkman B.M., Huizinga T.W., Kurban S.S., van der Velde E.A., Schreuder G.M., Hazes J.M., Breedveld F.C., Verweij C.L. Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br. J. Rheumatol. 36:1997;516-521.
6. Canella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
7. Coclet-Ninin J., Dayer J.M., Burger D. Interfereon-beta not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine. Netw. 8:(4):1997;345-349.
8. Crusius J.B.A., Pena A.S., van Oosten B.W., Bioque G., Garcia A., Dijkstra C.D., Polman C.H. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet. 346:(8980):1995;979-980.
9. Danis Y.A., Millington M., Hyland V.J., Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1ra) gene polymorphism. Clin. Exp. Immunol. 99:1995;303-310.
10. De la Concha E.G., Arroyo R., Crusius J.B.A., Campillo J.A., Martin C., Varela de Seijas E., Pena A.S., Claveria L.E., Fernandez-Arquero M. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele-2 in susceptibility to relapsing/remitting multiple sclerosis. J. Neuroimmunol. 80:1997;172-178.
11. Dinarello C.A., Wolff S.M. The role of interleukin-1 in disease. N. Engl. J. Med. 328:(2):1993;106-113.
12. Dinarello C.A. Interleukin-1. Thompson A. The Cytokine Handbook. 2nd Edition :1994;31 Academic Press, London, UK.
13. Heresbach D., Alizadeh M., Dabadie A., Le Berre N., Colombel J.F., Yaouanq J., Bretagne J.F., Semana G. Significance of interleukin-1 beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am. J. Gastroenterol. 92:(7):1997;1164-1169.
14. Huang W.X., He B., Hillert J. An interleukin 1-receptor antagonist gene polymorphism is not associated with multiple sclerosis. J. Neuroimmunol. 67:1996;143-144.
15. Kantarci O., Siva A., Eraksoy M., Karabudak R., Sutlas N., Agaoglu J., Turan F., Ozmenoglu M., Togrul E., Demirkiran M. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology. 51:(3):1998;765-772.
16. Khoury S.J., Akalin E., Chandraker A., Turka L.A., Linsley P.S., Sayegh M.H., Hancock W.W. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155:1995;4521-4524.
17. Manetti R., Barak V., Piccinni M.P., Sampognaro S., Parronchi P., Maggi E., Dinarello C.A., Romagnani S. Interleukin-1favours the in vitro development of type 2 T helper (Th2) human T-cell clones. Res. Immunol. 145:(2):1994;93-100.
18. Martin D., Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 61:1995;241-245.
19. Myhr K.M., Raknes G., Nyland H., Vedeler C. Immunoglobulin G Fc-receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS. Neurology. 52:(9):1999;1771-1776.
20. Nicklin M.J., Weith A., Duff G.W. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics. 19:(2):1994;382-384.
21. Nicoletti F., Patti F., DiMarco R., Zaccone P., Nicoletti A., Meroni P., Reggio A. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 8:(5):1996;395-400.
22. Pociot F., M∅lvig J., Wogensen L. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur. J. Clin. Invest. 22:1992;396-402.
23. Rodriguez M., Siva A., Ward J., Stolp-Smith K., O'Brien P., Kurland L. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology. 44:1994;78-83.
24. Schrijver H.M., Crusius J.B.A., Uitdehaag B.M.J., Garcia Gonzalez M.A., Kostense P.J., Polman C.H., Pena A.S. Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology. 52:(3):1999;595-599.
25. Sciacca F.L., Ferri C., Vandenbroeck K., Veglia F., Gobbi C., Martinelli F., Franciotta D., Zaffaroni M., Marrosu M., Martino G., Martinelli V., Comi G., Canal N., Grimaldi L.M.E. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology. 52:(9):1999;1896-1898.
26. Semana G., Yaouanq J., Alizadeh M., Clanet M., Edan G. Interleukin-1 receptor antagonist gene in multiple sclerosis (research letters). The Lancet. 349:(9050):1997;476.
27. Steinkasserer A., Spurr N.K., Cox S., Jeggo P., Sim R.B. The human IL-1 receptor antagonist gene (IL-1rn) maps to chromosome 2q14-21 in the region of the IL-1α and IL-1β loci. Genomics. 13:1992;654-657.
28. Tarlow J.K., Blakemore A.I., Lennard A., Solari R., Hughes H.N., Steinkasserer A., Duff G.W. Polymorphism in human IL-1 receptor antagonist gene intron is caused by a variable numbers of an 85-bp tandem repeat. Hum. Genet. 91:(4):1993;403-404.
29. Tarlow J.K., Clay F.E., Cork M.J., Blakemore A.I., McDonagh A.J., Messenger A.G., Duff G.W. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J. Invest. Dermatol. 103:(3):1994;387-390.
30. Wansen K., Pastinen T., Kuokkanen S., Wikstrom J., Palo J., Peltonen L., Tienari P.J. Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCRβ, IGH, IFN-γ and IL-1ra/IL-1β loci. J. Neuroimmunol. 79:1997;29-36.
31. Weinshenker B.G. The natural history of multiple sclerosis. Neurol. Clin. 1:1995;119-146.
32. Weinshenker B.G., Wingerchuk D.M., Liu Q., Bissonet A.S., Schaid D.J., Sommer S.S. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology. 49:(2):1997;378-385.
33. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology. 51:(3):1998;742-747.
34. Weir W.S. Genetic Data Analysis II. 1996;91-140 Sinauer, Massachusetts.